Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

"PrEP reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Although there is less ...

Cidara Therapeutics (CDTX) announced it has reached full planned enrollment of 5,000 subjects in the Phase 2b NAVIGATE trial across clinical ...

The Department of Health Western Visayas is intensifying its call for increased testing for human immunodeficiency virus (HIV ...

Approved by the FDA 12 years ago, pre-exposure prophylaxis (PrEP) has significantly reduced the risk of HIV transmission and ...

Considerable scale-up is needed to achieve the 2025 goals for HIV pre-exposure prophylaxis (PrEP), according to study findings.

On Worlds AIDS Day, the benefits of PEPFAR, PrEP, and U=U are celebrated. But continuing stigma and decreasing political will ...

A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...

But Woodward said the increase could be slowed down if there was greater uptake in drugs that prevent HIV transmission, ...

Memphis has one of the highest rates of HIV diagnoses in the United States, with new data showing a steady increase in cases ...

Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...

Yesterday, World AIDS Day, Bay Area church services acknowledged lives lost in the HIV/AIDS pandemic and elected officials ...